Side-by-side · Research reference

BronchogenvsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED16/35 cited

BHuman-MechanisticAUTO-DRAFTED8/37 cited

Bronchogen

Tetrapeptide Bioregulator · Khavinson-School

0.05 ng/mLEffective concentrationZakutskiĭ 2006

60 daysCOPD model durationTitova 2017

30 daysTreatment courseKuzubova 2015

Research models: tissue culture / parenteral

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

Bronchogen

Epitalon

Primary target

Bronchial epithelial cellsKuzubova 2015

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

Tissue-specific bioregulation → epithelial cell differentiation → ciliated cell restoration

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Reversal of goblet cell hyperplasia, squamous metaplasia elimination, restoration of ciliated epithelium, normalized secretory IgA and surfactant protein B productionKuzubova 2015 Titova 2017

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

—

Origin

Synthetic tetrapeptide (Ala-Glu-Asp-Leu) from Khavinson bioregulator framework

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

Bronchogen

Epitalon

Effective concentration (culture)

0.05 ng/mLZakutskiĭ 2006

Demonstrated in organotypic tissue culture of bronchial explants.

—

Treatment duration (animal)

1 month (30 days)Kuzubova 2015 Titova 2017

Course duration in rat COPD models.

—

Evidence basis

Animal models (rat) / organotypic cultureTitova 2017 Kuzubova 2015 Zakutskiĭ 2006

No human clinical trials reported in available literature.

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Model system

NO₂-induced COPD (60-day intermittent exposure)Titova 2017

—

Tissue specificity

Selective for bronchopulmonary tissue

Part of Khavinson organ-specific bioregulator series.

—

Standard dose

—

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Frequency

—

Once daily during a cycle

Lower / starter dose

—

2.5 mg / day

Duration

—

10–20 day cycles, 1–2× per year

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep preferred (pineal alignment)

Half-life

—

Hours (estimated)

04Side Effects & Safety

Parameter

Bronchogen

Epitalon

Animal safety profile

No adverse effects reported in published rat studies

Limited safety data; only animal models available.

—

Human data

Absent — no clinical trials in humans reported

—

Long-term effects

Unknown — maximum study duration 30 days in animals

—

Injection site reaction

—

Mild irritation

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Cancer risk

—

Theoretical via telomerase activation in pre-malignant cells

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Antibody formation

—

Not reported

Absolute Contraindications

Bronchogen

—

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

Bronchogen

—

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

Bronchogen

Epitalon

1. Research context only

Bronchogen has been studied exclusively in animal models and organotypic tissue culture. No approved formulation or human administration protocol exists.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Animal model protocol

In rat COPD models, tetrapeptide administered for 30-day course following 60-day NO₂ exposure. Route and exact dosing not specified in abstracts.Titova 2017 Kuzubova 2015

SQ — abdomen preferred. Rotate sites.

3. Organotypic culture

Bronchial tissue explants from young (3-week) and aged (18-month) rats cultured in medium containing 0.05 ng/mL bronchogen, demonstrating tissue-specific stimulation.Zakutskiĭ 2006

Pre-sleep preferred to align with pineal axis.

4. Khavinson bioregulator tradition

Part of Russian peptide bioregulator framework emphasizing tissue-specific low-dose effects. Typically administered parenterally in related peptides from this series.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.